Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.76 |
| ▸ | RAB9A | P51151 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | TP53 | P04637 | 4/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.76 |
| ▸ | RELA | Q04206 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | AR | P10275 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802217 | 0.89 | NPC1 (0.83) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL8363735 | 0.87 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL12167724 | 0.87 | AR (0.89) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL5400469 | 0.87 | AR (0.89) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL5226157 | 0.86 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL94789 | 0.85 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2TP53NFKB1 | |
| SCHEMBL5333933 | 0.85 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL6815681 | 0.85 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL30949327 | 0.85 | AR (0.87) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL30455725 | 0.85 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | NPC1 2361/4885RAB9A 3886/4885SMN1; SMN2 3998/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | NPC1 2922/4885RAB9A 2273/4885SMN1; SMN2 3084/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | NPC1 2922/4885RAB9A 2273/4885SMN1; SMN2 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.